Listed by the USPTO as DAVIS, BRIAN J
Tech Center 1600 • Art Units: 1612 1614 1615 1621 1627 1672
This examiner grants 85% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18551809 | COMPOSITE DRUG PARTICLES AND USES THEREOF | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 19011409 | BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF | Non-Final OA | Massachusetts Institute of Technology |
| 18541680 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 19033776 | UTILIZATION OF NANOPARTICLES IN TARGETED THERAPY | Non-Final OA | Alcon Inc. |
| 19104187 | NATURAL-BASED SALICYLIC ACID POLY(ANHYDRIDE ESTER) HYDROGELS FOR AGRICULTURAL APPLICATIONS | Non-Final OA | The Regents of The University of California |
| 18285439 | IMMUNOFUNCTIONAL CARRIER, METHODS OF USES, AND COMPOSITION MATTERS AS AN ANTITUMOR IMMUNOTHERAPY | Non-Final OA | Purdue Research Foundation |
| 18880931 | Liquid Emulsion Comprising Ethylcellulose, a Natural Resin, a Liquid Fatty Alcohol, a Solid Ester and/or a Polar Hydrocarbon-Based Oil and Process Using Same | Non-Final OA | L'OREAL |
| 18870026 | HAIR TREATMENT METHOD FOR LIMITING THE CALCIUM CONTENT OF THE HAIR | Non-Final OA | L'OREAL |
| 18898187 | COMPOSITIONS AND METHODS FOR TREATING HAIR | Non-Final OA | L'Oreal |
| 18292746 | COSMETIC TREATMENT METHOD COMPRISING THE APPLICATION OF A COMPOSITION COMPRISING AT LEAST ONE ANTIOXIDANT AND A BIFIDOBACTERIUM SPECIES LYSATE | Final Rejection | L'Oreal |
| 18703046 | METHOD FOR PRODUCING EMULSION COMPOSITION | Non-Final OA | KAO CORPORATION |
| 18856855 | BIODEGRADABLE LIPIDOIDS AND COMPOSITIONS AND METHODS OF USE THEREOF FOR TARGETED DELIVERY | Non-Final OA | The Trustees Of The University Of Pennsylvania |
| 18291488 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | Non-Final OA | ROQUETTE FRERES |
| 18794848 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18725296 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOSITIONS | Non-Final OA | GIVAUDAN SA |
| 18831041 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | Final Rejection | Nammi Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy84.8% of resolved applications examined by Brian J Davis were allowed (1,592 resolved cases), compared with 40.7% across Art Unit 1612 over the last five years.
This examiner's interview lift is -3.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Brian J Davis took 639 days on average from filing to allowance.
Brian J Davis examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
